<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        18-475-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XGEVA 120 mg solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DENOSUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1623.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AMGEN MANUFACTURING LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AMGEN MANUFACTURING LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AMGEN EUROPE B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>XGEVA contains denosumab, a protein (monoclonal antibody) that works to slow down bone destruction caused by cancer spreading to the bone (bone metastasis) or by giant cell tumour of bone.</p><p>&nbsp;</p><p>XGEVA is used in adults with advanced cancer to prevent serious complications caused by bone metastasis (e.g. fracture, pressure on the spinal cord or the need to receive radiation therapy or surgery).</p><p>&nbsp;</p><p>XGEVA is also used to treat giant cell tumour of bone, which cannot be treated by surgery or where surgery is not the best option, in adults and adolescents whose bones have stopped growing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use XGEVA</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to denosumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p>Your doctor or healthcare professional will not administer XGEVA to you if you have a very low level of calcium in your blood which has not been treated.</p><p>&nbsp;</p><p>Your doctor or healthcare professional will not administer XGEVA to you if you have unhealed wounds from dental or oral surgery.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor before using XGEVA</strong></p><p>&nbsp;</p><p><u>Calcium and vitamin&nbsp;D supplementation</u></p><p>You should take calcium and vitamin&nbsp;D supplements while being treated with XGEVA unless your blood calcium is high. Your doctor will discuss this with you. If the level of calcium in your blood is low, your doctor may decide to give you calcium supplements before you start treatment with XGEVA.</p><p>&nbsp;</p><p><u>Low calcium levels in the blood</u></p><p>Please tell your doctor immediately if you have spasms, twitches, or cramps in your muscles, and/or numbness or tingling in your fingers, toes or around your mouth and/or seizures, confusion or loss of consciousness while being treated with XGEVA. You may have low levels of calcium in your blood.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Tell your doctor if you have or have had severe kidney problems, kidney failure or have needed dialysis, which may increase your risk of getting low blood calcium, especially if you do not take calcium supplements.</p><p>&nbsp;</p><p><u>Problems with your mouth, teeth or jaw</u></p><p>A side effect called osteonecrosis of the jaw (bone damage in the jaw) has been reported commonly (may affect up to 1 in 10&nbsp;people) in patients receiving XGEVA injections for cancer-related conditions. Osteonecrosis of the jaw can also occur after stopping treatment.</p><p>&nbsp;</p><p>It is important to try to prevent osteonecrosis of the jaw developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before receiving treatment, tell your doctor/healthcare professional if you have any problems with your mouth or teeth. Your doctor should delay the start of your treatment if you have unhealed wounds in your mouth from dental procedures or oral surgery. Your doctor may recommend a dental examination before you start treatment with XGEVA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While being treated, you should maintain good oral hygiene and receive routine dental check-ups. If you wear dentures, you should make sure these fit properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with XGEVA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw.</p><p><strong>&nbsp;</strong></p><p>Patients undergoing chemotherapy and/or radiotherapy, taking steroids or anti-angiogenic medicines (used to treat cancer), undergoing dental surgery, who do not receive routine dental care, have gum disease, or who are smokers may have a higher risk of developing osteonecrosis of the jaw.</p><p>&nbsp;</p><p><u>Unusual thigh bone fractures</u></p><p>Some people have developed unusual fractures in their thigh bone while being treated with XGEVA. Contact your doctor if you experience new or unusual pain in your hip, groin, or thigh.</p><p><u>&nbsp;</u></p><p><u>High calcium levels in the blood after stopping treatment with XGEVA</u></p><p>Some patients with giant cell tumour of the bone have developed high calcium levels in the blood weeks to months after stopping treatment. Your doctor will monitor you for signs and symptoms of high levels of calcium, after you stop receiving XGEVA.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>XGEVA is not recommended for children and adolescents under 18&nbsp;years of age except for adolescents with giant cell tumour of the bone whose bones have stopped growing. The use of XGEVA has not been studied in children and adolescents with other cancers that have spread to bone.</p><p>&nbsp;</p><p><strong>Other medicines and XGEVA</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription. It is especially important that you tell your doctor if you are being treated with</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; another medicine containing denosumab</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a bisphosphonate</p><p>&nbsp;</p><p>You should not take XGEVA together with other medicines containing denosumab or bisphosphonates.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>XGEVA has not been tested in pregnant women. It is important to tell your doctor if you are pregnant, think you may be pregnant, or plan to get pregnant. XGEVA is not recommended for use if you are pregnant. Women of child-bearing potential should use effective methods of contraception while being treated with XGEVA and for at least 5&nbsp;months after stopping treatment with XGEVA.</p><p>&nbsp;</p><p>If you become pregnant during treatment with XGEVA or less than 5&nbsp;months after stopping treatment with XGEVA, please inform your doctor.</p><p>&nbsp;</p><p>It is not known whether XGEVA is excreted in breast milk. It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast‑feeding or whether to stop taking XGEVA, considering the benefit of breast-feeding to the baby and the benefit of XGEVA to the mother.</p><p>&nbsp;</p><p>If you are nursing during treatment with XGEVA, please inform your doctor.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>XGEVA has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>XGEVA contains sorbitol</strong></p><p>&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine, since it contains sorbitol (E420).</p><p>&nbsp;</p><p><strong>XGEVA contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 120&nbsp;mg, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>XGEVA should be administered under the responsibility of a healthcare professional.</p><p>&nbsp;</p><p>The recommended dose of XGEVA is 120&nbsp;mg administered once every 4&nbsp;weeks, as a single injection under the skin (subcutaneous). XGEVA will be injected into your thigh, abdomen or upper arm. If you are being treated for giant cell tumour of bone, you will receive an additional dose 1&nbsp;week and 2&nbsp;weeks after the first dose.</p><p>&nbsp;</p><p>Do not shake.</p><p>&nbsp;</p><p>You should also take calcium and vitamin&nbsp;D supplements while being treated with XGEVA unless you have an excess of calcium in the blood. Your doctor will discuss this with you.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Please tell your doctor immediately</strong> if you develop any of these symptoms while being treated with XGEVA (may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spasms, twitches, cramps in your muscles, numbness or tingling in your fingers, toes or around your mouth and/or seizures, confusion or loss of consciousness. These could be signs that you have low calcium levels in the blood. Low calcium in the blood may also lead to a change in heart rhythm called QT prolongation, which is seen by electrocardiogram (ECG).</p><p>&nbsp;</p><p><strong>Please tell your doctor and dentist immediately</strong> if you experience any of these symptoms while being treated with XGEVA or after stopping treatment (may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent pain in the mouth and/or jaw, and/or swelling or non-healing of sores in the mouth or jaw, discharge, numbness or feeling of heaviness in the jaw, or loosening of a tooth could be signs of bone damage in the jaw (osteonecrosis).</p><p>&nbsp;</p><p><strong>Very common side effects</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone, joint, and/or muscle pain which is sometimes severe,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea.</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects</strong> (may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low phosphate levels in the blood (hypophosphataemia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; removal of a tooth,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with advanced cancer: development of another form of cancer.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high calcium levels in the blood (hypercalcaemia) after stopping treatment in patients with giant cell tumour of the bone,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new or unusual pain in your hip, groin or thigh (this may be an early indication of a possible fracture of the thigh bone),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash that may occur on the skin or sores in the mouth (lichenoid drug eruptions).</p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects</strong> (may affect up to 1 in 1,000&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (e.g. wheezing or difficulty breathing; swelling of the face, lips, tongue, throat or other parts of the body; rash, itching or hives on the skin). In rare cases allergic reactions may be severe.</p><p><strong>&nbsp;</strong></p><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could be signs of bone damage in the ear.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&nbsp;&deg;C&nbsp;&ndash;&nbsp;8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>The vial may be left outside the refrigerator to reach controlled room temperature (up to 25&nbsp;&deg;C) before injection. This will make the injection more comfortable. Once your vial has been left to reach room temperature (up to 25&nbsp;&deg;C), it must be used within 30&nbsp;days.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is denosumab. Each vial contains 120&nbsp;mg of denosumab in 1.7&nbsp;mL of solution (corresponding to 70&nbsp;mg/mL).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients in each 1&nbsp;vial are: acetic acid glacial (1.8&nbsp;mg), sodium hydroxide (for pH adjustment to a target of&nbsp;5.2), sorbitol E420 (78.1&nbsp;mg), polysorbate&nbsp;20 (0.17&nbsp;mg) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                XGEVA is a solution for injection (injection).

	XGEVA is a clear, colourless to slightly yellow solution. It may contain trace amounts of clear to white particles.

Each pack contains one, three or four single use vials.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amgen Europe B.V.</p><p>Minervum 7061</p><p>NL-4817 ZK Breda</p><p>The Netherlands</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                		This leaflet was last revised in November 2019.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي اكسجيفا على مادة دينوسوماب وهي بروتين (جسم مضاد أحادي النسيلة) يعمل على إبطاء تدمير العظام الناتج عن انتشار السرطان في العظام (انبثاث العظام) أو ورم الخلايا العملاقة في العظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويستخدم اكسجيفا لدى البالغين المصابين بالسرطان المتقدم لتجنب المضاعفات الخطيرة التي يسببها انبثاث العظام (مثل الكسر أو الضغط على الحبل الشوكي أو ضرورة تلقي علاج إشعاعي أو جراحة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما أن اكسجيفا يستخدم لعلاج ورم الخلايا العملاقة في العظام، والتي لا يمكن علاجها عن طريق الجراحة أو حيث أن الجراحة ليست الخيار الأفضل، لدى البالغين والمراهقين الذين توقفت عظامهم عن النمو.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم اكسجيفا في الحالات التالية</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه دينوسوماب أو أي مكون آخر من مكونات هذا الدواء (مدرَج في القسم&nbsp;٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لن يصف لك متخصص الرعاية الصحية اكسجيفا إذا كنت تعاني من انخفاض حاد في مستوى الكالسيوم في الدم الذي لم يعالج لديك بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لن يصف لك طبيبك أو متخصص الرعاية الصحية الخاص بك اكسجيفا إذا كنت تعاني من جروح غير ملتئمة جراء جراحة بالفم أو الأسنان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك قبل استخدام اكسجيفا.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مكملات الكالسيوم والفيتامين&nbsp;د</u></p><p dir="RTL">ينبغي تناول مكملات الكالسيوم والفيتامين&nbsp;د أثناء العلاج باستخدام اكسجيفا إلا في حالة ارتفاع مستوى الكالسيوم في الدم لديك، وهو الأمر الذي سيناقشه معك طبيبك، إذا كان مستوى الكالسيوم لديك منخفض، قد يقرر الطبيب وصف مكملات الكالسيوم قبل بداية العلاج باستخدام اكسجيفا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>انخفاض مستوى الكالسيوم في الدم</u></p><p dir="RTL">الرجاء إخبار طبیبك فورا إذا تعرضت عضلاتك لتشنجات أو نفضات أو تقلصات (مَعَص) و/أو أحسست بتخدر أو نخز (تنمیل) في أصابع یدیك أو قدمیك أو حول فمك و/أو إذا تعرضت لنوبات اختلاجیة، أو لتشوش في الذهن أو فقدان الوعي أثناء تلقیك العلاج باستخدام اكسجيفا. فقد تكون مستویات الكالسیوم في دمك منخفضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>القصور الكلوي</u></p><p dir="RTL">أخبر طبیبك إذا كنت تعاني أوعانيت في وقت سابق من مشاكل حادة في الكلى أو فشل كلوي أو تحتاج إلى غسيل كلى مما قد يزيد من خطر الاصابة بانخفاض مستوى الكالسيوم في الدم خاصة في حالة عدم تناولك لمكملات الكالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مشاكل في الفم أو الأسنان أو الفك</u></p><p dir="RTL">ومن الآثار الجانبية، تنخر عظم الفك (تلف العظم بالفك) وقد تم الإبلاغ عنه بصفة شائعة (قد يصيب ١ عن كل ١٠&nbsp;أشخاص) لدى المرضى الذين يتلقون الحقن باكسجيفا في نطاق الحالات المتعلقة بالسرطان. يمكن أيضا أن يحدث تنخر العظم بالفك بعد وقف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ومن المهم محاولة الوقاية من الإصابة بتنخر العظم بالفك لأنها من الممكن أن تكون حالة مؤلمة من الصعب علاجها. من أجل الحد من خطر الإصابة بتنخر العظم في الفك، هناك بعض الاحتياطات التي يجب عليك اتخاذها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل تلقي العلاج، أخبر الطبيب/متخصص الرعاية الصحية إذا كان لديك أي مشاكل بالفم أو الأسنان. يجب على طبيبك أن يؤخر بدء العلاج الخاص بك إذا كنت تعاني من جروح لا تلتئم في الفم جراء إجراءات على مستوى الأسنان أو جراحة الفم. قد يوصي طبيبك بإجراء فحص الأسنان قبل بدء العلاج باكسجيفا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء العلاج، يجب الحفاظ على نظافة فم جيدة وتلقي فحوصات الأسنان الروتينية. إذا كنت تحمل طقم أسنان، يجب عليك التأكد من أنه يناسبك جيدا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بصدد تلقي علاج على مستوى الأسنان أو ستخضع لجراحة على مستوى الأسنان (مثل قلع ضرس)، عليك بإخبار طبيبك حول علاج الأسنان الخاص بك وأخبر طبيب أسنانك أنك تعالج باكسجيفا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيبيك أو طبيب أسنانك فورا إذا تعرضت لأیة مشاكل في الفم أو الأسنان مثل أسنان مقلقلة أو ألم أو تورم أو جروح لا تلتئم أو افرازات، فقد تكون علامات من تنخر عظم الفك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يزداد احتمال التعرض لتنخرعظم الفك بالنسبة للمرضى الذين يتلقون علاجا كيميائيا و/أو بالإشعاع أو يتناولون الستیرویدات أو الأدوية المضادة للعائية (التي تستخدم لعلاج السرطان)، أو أجروا جراحة بالفم أو لا يتلقون عناية منتظمة بأسنانهم، أو يعانون من مرض في اللثة، أو هم من المدخنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>كسورغيرعادية بعظم الفخذ</u></p><p dir="RTL">لقد عانى بعض الأشخاص من كسور غير عادية بعظم أفخاذهم أثناء العلاج باستخدام اكسجيفا. اتصل بطبيبك إذا أحسست بألم جديد أو غير عادي في الورك، الأربية، أو الفخذ.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>ارتفاع مستويات الكالسيوم في الدم بعد التوقف عن العلاج باكسجيفا</u></p><p dir="RTL">أظهر بعض المرضى الذين يعانون من ورم الخلايا العملاقة في العظام مستويات عالية من الكالسيوم في الدم خلال فترة تتراوح بين أسابيع إلى أشهر بعد التوقف عن العلاج. سيقوم طبيبك بفحصك للكشف عن علامات وأعراض ارتفاع مستويات الكالسيوم، بعد أن تتوقف عن تلقي اكسجيفا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوصى باستخدام اكسجيفا لدى الأطفال والمراهقين دون سن ١٨&nbsp;عاما باستثناء المراهقين الذين يعانون من ورم الخلايا العملاقة في العظام وتوقفت عظامهم عن النمو. حيث لم تتم دراسة استخدام اكسجيفا لدى الأطفال والمراهقين الذين يعانون من أنواع أخرى من السرطان الذي انتشر إلى العظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدويــة أخـــرى واكسجيفا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">الرجاء إخبار الطبيب أو الصيدلي الذي تتعامل معه إذا كنت تتناول أو تناولت في الآونة الأخيرة أو قد تقوم بتناول أدوية أخرى، وذلك يشمل الأدوية التي حصلت عليها بدون وصفة طبية. ومن الضروري إخبار طبيبك إذا كنت تعالج بما يلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي دواء يحتوي على الدينوسوماب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البیسفوسفونات</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي تناول اكسجيفا مع أي دواء آخر يحتوي على الدينوسوماب أو البیسفوسفونات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يتم اختباراكسجيفا لدى الحوامل. ومن الضروري إخبار طبيبك إذا كنت حاملا، أو تعتقدين أنك حاملا، أو تخططين للحمل. ولا يوصى باستخدام اكسجيفا إذا كنت حاملا. ينبغي أن تستخدم السيدات اللواتي تتوقعن الإنجاب طرق منع حمل فعالة أثناء العلاج باستخدام اكسجيفا ولمدة خمسة&nbsp;أشهر على الأقل بعد التوقف عن العلاج باستخدام اكسجيفا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا اكتشفت أنك حاملا أثناء العلاج باكسجيفا أو أقل من خمسة&nbsp;أشهر بعد التوقف عن العلاج باكسجيفا، يرجى الاتصال بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف إذا كان اكسجيفا يتم إفرازه في حليب الرضاعة الطبيعية. ومن المهم إخبار طبيبك إذا كنت ترضعين أو تخططين لذلك. سيساعدك الطبيب بدوره في اتخاذ قرار وقف الرضاعة أو وقف العلاج باستخدام اكسجيفا، نظرا لأهمية الإرضاع الطبيعي للمولود وحسب فوائد العلاج باستخدام اكسجيفا للأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت ترضعين أثناء العلاج باكسجيفا، يرجى الاتصال بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عليك استشارة الطبيب أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يؤثر تناول اكسجيفا أو له تأثير ضئيل على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي اكسجيفا على السوربيتول</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أخبرك طبيبك بأنك تعاني من الحساسية تجاه بعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء، حيث يحتوي على سوربيتول (٤٢٠&rlm;E).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي اكسجيفا على الصوديوم</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ١&nbsp;ملمول صوديوم (٢۳&nbsp;مجم) لكل ١٢٠&nbsp;مجم، أي يعتبر أساسا &quot;خال من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يتم إعطاء اكسجيفا تحت مسؤولية متخصص الرعاية الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة التي يوصى بها من اكسجيفا هي ١٢٠&nbsp;مجم مرة كل أربعة&nbsp;أسابيع، على شكل حقنة واحدة تحت الجلد. ويتم حقن اكسجيفا في الفخذ، أو البطن أو الجزء العلوي من الذراع. إذا كنت تعالج من ورم الخلايا العملاقة في العظام، سوف تتلقى جرعة إضافية بعد أسبوع وبعد أسبوعين من الجرعة الأولى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ترج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تناول مكملات الكالسيوم وفيتامين&nbsp;د أثناء العلاج باستخدام اكسجيفا ما لم يكن لديك ارتفاع في مستوى الكالسيوم في الدم. سيناقشك طبيبك في هذا الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة المزيد من الأسئلة بشأن استخدام هذا الدواء، يرجى مراجعة الطبيب، الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء كغيره من الأدوية آثارا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يرجى إخبار طبيبك فور</strong> حدوث أي من الأعراض التالية أثناء العلاج باستخدام اكسجيفا (قد يصيب أكثر من شخص واحد عن كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات، شد، تقلصات في العضلات، تخدر أو وخز في أصابع اليدين، والقدمين أو حول الفم و/أو إذا تعرضت لنوبات اختلاجیة، أو لتشوش في الذهن أو فقدان الوعي. يمكن أن تكون هذه علامات انخفاض مستويات الكالسيوم في الدم. قد يؤدي انخفاض الكالسيوم بالدم إلى تغير في نظم القلب يظهر بالتخطيط الكهربائي البياني للقلب (ECG&rlm;)، واسمه استطالة QT.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يرجى إخبار طبيبك أو طبيب أسنانك فور</strong> حدوث أي من الأعراض التالية أثناء العلاج باستخدام اكسجيفا أو بعد إيقاف العلاج (قد يصيب إلى حدود شخص واحد عن كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم مستمر في الفم و/أو الفك، و/أو تورم أو عدم شفاء من تقرحات بالفم أو الفك، افرازات، تخدير أو شعور بثقل بالفك، أو أسنان مقلقلة وقد تعتبر هذه علامات ضعف عظام الفك (تنخر العظام).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدا</strong> (قد تصيب أكثر من ١ عن كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم قد يكون شديدا في بعض الأحيان، في العظام و/أو المفاصل و/أو العضلات،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور النفس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تصيب إلى حدود شخص واحد عن كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الفوسفات في الدم (نقص الفوسفات في الدم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلع سن،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق المفرط،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدى المرضى المصابين بمرحلة متقدمة من السرطان: تطور شكل آخر من أشكال السرطان.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong>(قد تصيب إلى حدود شخص واحد عن كل ١٠٠&nbsp;شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الكالسيوم في الدم (فرط كالسيوم الدم) بعد التوقف عن العلاج لدى المرضى الذين يعانون من ورم الخلايا العملاقة في العظام،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم جديد أو غير عادي في الورك، الأربية أو الفخذ (قد يكون ذلك علامة مبكرة عن إمكانية حدوث كسر في عظم الفخذ)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي قد يظهر على الجلد أو تقرحات بالفم (طفوح جلدية حزازية الشكل ناتجة من الدواء).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية النادرة </strong>(قد تصيب إلى حدود شخص واحد عن كل ١٠٠٠&nbsp;شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (مثل صفير أو صعوبة في التنفس؛ تورم الوجه، الشفاه، اللسان، الحنجرة أو أي أجزاء أخرى من الجسم؛ طفح جلدي، حكة، أو شرى على الجلد). وفي حالات نادرة قد تكون التفاعلات الحساسية شديدة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير المعروف</strong> (لا يمكن تقدير التكرار من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﺤﺪث إلى ﻃﺒﻴﺒﻚ إذا كنت ﺗﻌﺎﻧﻲ ﻣﻦ أﻟﻢ ﻓﻲ اﻷذن، أو ﺗﻔﺮﻳﻎ ﻣﻦ اﻷذن، و/أو إﺻﺎﺑﺔ الأذن بالعدوى. قد تكون هذه علامات على تلف عظام الأذن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، يرجى إبلاغ طبيبك، الصيدلي أو الممرضة. ويشمل ذلك أي آثار جانبية غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بالدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العلبة وورقة القنينة. يشير تاريخ انتهاء الصلاحية لآخر يوم في الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن في الثلاجة (٢&deg;م&nbsp;‑&nbsp;٨&deg;م).</p><p dir="RTL">لا يجمد.</p><p dir="RTL">احتفظ بالقنينة في العلبة الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن ترك القنينة خارج الثلاجة لتصل إلى درجة حرارة الغرفة (تصل إلى ٢٥&nbsp;&deg;م) قبل الحقن. وهو ما يسهل عملية الحقن. عندما تصل القنينة لدرجة حرارة الغرفة (تصل إلى ٢٥&nbsp;&deg;م)، يجب استخدامها خلال ۳٠&nbsp;يوما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم رمي الأدوية بالقرب من مياه الصرف أو الفضلات المنزلية. وعليك باستشارة الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها. فمثل تلك الإجراءات تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">عما يحتوي اكسجيفا</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعتبر دينوسيوماب هو المادة الفعالة. تحتوي كل قنينة على ١٢٠ مجم من دينوسيوماب في ١٫٧ مل من المحلول (ما يعادل ٧٠&nbsp;مجم/مل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى في كل قنينة ھي :حامض الأستيك الجلاسيال) ١٫٨ مجم(، وهيدروكسيد الصوديوم) لتعدیل PH لاستھداف ٥٫٢ (، وسوربيتول ٤٢٠E (٧٨٫١ مجم(، بوليسوربات ٢٠) ٠٫١٧ مجم( وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شكل اكسجيفا ومحتويات العبوة</p><p dir="RTL">&nbsp;</p><p dir="RTL">اكسجيفا هو عبارة عن محلول للحقن (حقنة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">اكسجيفا هو عبارة عن محلول صاف غير ملون أو مائل للون الأصفر وقد يحتوي على كميات ضئيلة من الجزيئات الشفافة أو بيضاء اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على قنينة، أو ثلاثة أو أربع قنينات للاستخدام مرة واحدة.</p><p dir="RTL">ليست كل أحجام العبوات للتسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Amgen Europe B.V.</p><p dir="RTL">Minervum 7061</p><p dir="RTL">&nbsp;NL-4817 ZK Breda</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أي معلومات حول هذا المنتج الدوائي، يرجى الاتصال بالمندوب المحلي لحامل حق التسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             	تم اعتماد هذه النشرة في نوفمبر ٢٠١٩.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XGEVA 120 mg solution for injection 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).

Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese hamster ovary cells) by recombinant DNA technology.

Excipient with known effects
Each 1.7 mL of solution contains 78 mg sorbitol (E420). 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).
Clear, colourless to slightly yellow solution and may contain trace amounts of translucent to white proteinaceous particles. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1)</p><p>&nbsp;</p><p>Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>XGEVA should be administered under the responsibility of a healthcare professional.</p><p>&nbsp;</p><p><u>Posology </u></p><p>&nbsp;</p><p>Supplementation of at least 500&nbsp;mg calcium and 400&nbsp;IU vitamin D daily is required in all patients, unless hypercalcaemia is present (see section 4.4).</p><p>&nbsp;</p><p>Patients treated with XGEVA should be given the package leaflet and the patient reminder card.</p><p>&nbsp;</p><p><em>Prevention of skeletal related events in adults with advanced malignancies involving bone </em></p><p>The recommended dose is 120&nbsp;mg administered as a single subcutaneous injection once every 4&nbsp;weeks into the thigh, abdomen or upper arm.</p><p>&nbsp;</p><p><em>Giant cell tumour of bone</em></p><p>The recommended dose of XGEVA is 120&nbsp;mg administered as a single subcutaneous injection once every 4&nbsp;weeks into the thigh, abdomen or upper arm with additional 120&nbsp;mg doses on days&nbsp;8 and 15 of treatment of the first month of therapy.</p><p>&nbsp;</p><p>Patients in the phase II study who underwent complete resection of giant cell tumour of bone did receive an additional 6&nbsp;months of treatment following the surgery as per study protocol.</p><p>&nbsp;</p><p>Patients with giant cell tumour of bone should be evaluated at regular intervals to determine whether they continue to benefit from treatment. In patients whose disease is controlled by XGEVA, the effect of interruption or cessation of treatment has not been evaluated, however limited data in these patients does not indicate a rebound effect upon cessation of treatment.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with renal impairment (see section 4.4 for recommendations relating to monitoring of calcium, 4.8 and 5.2).</p><p>&nbsp;</p><p><em>&nbsp;Hepatic impairment</em></p><p>The safety and efficacy of denosumab have not been studied in patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly patients (age&nbsp;&ge;&nbsp;65)</em></p><p>No dose adjustment is required in elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>The safety and efficacy of XGEVA have not been established in paediatric patients (age &lt;&nbsp;18) other than skeletally mature adolescents (aged 12‑17&nbsp;years) with giant cell tumour of bone.</p><p>&nbsp;</p><p>XGEVA is not recommended in paediatric patients (age&nbsp;&lt;&nbsp;18) other than skeletally mature adolescents (aged 12‑17&nbsp;years) with giant cell tumour of bone (see section 4.4).</p><p>&nbsp;</p><p>Treatment of skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity: the posology is the same as in adults.</p><p>&nbsp;</p><p>Inhibition of RANK/RANK ligand (RANKL) in animal studies has been coupled to inhibition of bone growth and lack of tooth eruption, and these changes were partially reversible upon cessation of RANKL inhibition (see section 5.3).</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>For subcutaneous use.</p><p>&nbsp;</p><p>&nbsp;For instructions for use, handling and disposal, see section 6.6.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Severe, untreated hypocalcaemia (see section 4.4).

Unhealed lesions from dental or oral surgery.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Calcium and Vitamin D supplementation </u></p><p><u>&nbsp;</u></p><p>Supplementation with calcium and vitamin D is required in all patients unless hypercalcaemia is present (see section 4.2).</p><p>&nbsp;</p><p><u>Hypocalcaemia</u></p><p><u>&nbsp;</u></p><p>Pre-existing hypocalcaemia must be corrected prior to initiating therapy with XGEVA. Hypocalcaemia can occur at any time during therapy with XGEVA. Monitoring of calcium levels should be conducted (i) prior to the initial dose of XGEVA, (ii) within two weeks after the initial dose, (iii) if suspected symptoms of hypocalcaemia occur (see section 4.8 for symptoms). Additional monitoring of calcium level should be considered during therapy in patients with risk factors for hypocalcaemia, or if otherwise indicated based on the clinical condition of the patient.</p><p>&nbsp;</p><p>Patients should be encouraged to report symptoms indicative of hypocalcaemia. If hypocalcaemia occurs while receiving XGEVA, additional calcium supplementation and additional monitoring may be necessary.</p><p>&nbsp;</p><p>In the post‑marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported (see section 4.8), with most cases occurring in the first weeks of initiating therapy, but can occur later.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>Patients with severe renal impairment (creatinine clearance&nbsp;&lt;&nbsp;30&nbsp;mL/min) or receiving dialysis are at greater risk of developing hypocalcaemia. The risk of developing hypocalcaemia and accompanying elevations in parathyroid hormone increases with increasing degree of renal impairment. Regular monitoring of calcium levels is especially important in these patients.</p><p>&nbsp;</p><p><u>Osteonecrosis of the jaw (ONJ)</u></p><p><u>&nbsp;</u></p><p>ONJ has been reported commonly<em> </em>in patients receiving XGEVA (see section 4.8).</p><p>&nbsp;</p><p>The start of treatment/new treatment course should be delayed in patients with unhealed open soft tissue lesions in the mouth. A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with denosumab.</p><p>The following risk factors should be considered when evaluating a patient&rsquo;s risk of developing ONJ:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potency of the medicinal product that inhibits bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to head and neck.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor oral hygiene, periodontal disease, poorly fitting dentures, pre-existing dental disease, invasive dental procedures (e.g. tooth extractions).</p><p>&nbsp;</p><p>All patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with denosumab. While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to XGEVA administration.</p><p>&nbsp;</p><p>The management plan of the patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of XGEVA treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.</p><p>&nbsp;</p><p><u>Osteonecrosis of the external auditory canal</u></p><p><u>&nbsp;</u></p><p>Osteonecrosis of the external auditory canal has been reported with denosumab. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving denosumab who present with ear symptoms including chronic ear infections.</p><p>&nbsp;</p><p><u>Atypical fractures of the femur </u></p><p><u>&nbsp;</u></p><p>Atypical femoral fractures have been reported in patients receiving denosumab (see section 4.8). Atypical femoral fractures may occur with little or no trauma in the subtrochanteric and diaphyseal regions of the femur. Specific radiographic findings characterise these events. Atypical femoral fractures have also been reported in patients with certain co‑morbid conditions (e.g. vitamin D deficiency, rheumatoid arthritis, hypophosphatasia) and with use of certain pharmaceutical agents (e.g. bisphosphonates, glucocorticoids, proton pump inhibitors). These events have also occurred without antiresorptive therapy. Similar fractures reported in association with bisphosphonates are often bilateral; therefore the contralateral femur should be examined in denosumab-treated patients who have sustained a femoral shaft fracture. Discontinuation of XGEVA therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient based on an individual benefit risk assessment. During denosumab treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated for an incomplete femoral fracture.</p><p>&nbsp;</p><p><u>Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone and in patients with growing skeletons</u></p><p><u>&nbsp;</u></p><p>Clinically significant hypercalcaemia requiring hospitalisation and complicated by acute renal injury has been reported in XGEVA‑treated patients with giant cell tumour of bone weeks to months following treatment discontinuation.</p><p>&nbsp;</p><p>After treatment is discontinued, monitor patients for signs and symptoms of hypercalcaemia, consider periodic assessment of serum calcium and re‑evaluate the patient&rsquo;s calcium and vitamin D supplementation requirements (see section&nbsp;4.8).</p><p>&nbsp;</p><p>XGEVA is not recommended in patients with growing skeletons (see section 4.2). Clinically significant hypercalcaemia has also been reported in this patient group weeks to months following treatment discontinuation.</p><p>&nbsp;</p><p><u>Others</u></p><p><u>&nbsp;</u></p><p>Patients being treated with XGEVA should not be treated concomitantly with other denosumab containing medicinal products (for osteoporosis indications).</p><p>&nbsp;</p><p>Patients being treated with XGEVA should not be treated concomitantly with bisphosphonates.</p><p>&nbsp;</p><p>Malignancy in giant cell tumour of bone or progression to metastatic disease is an infrequent event and a known risk in patients with giant cell tumour of bone. Patients should be monitored for radiological signs of malignancy, new radiolucency or osteolysis. Available clinical data does not suggest an increased risk of malignancy in giant cell tumour of bone patients treated with XGEVA.</p><p>&nbsp;</p><p><u>Warnings for excipients</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicinal product.</p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 120&nbsp;mg, i.e. essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No interaction studies have been performed.</p><p>&nbsp;</p><p>In clinical trials, XGEVA has been administered in combination with standard anti-cancer treatment and in subjects previously receiving bisphosphonates. There were no clinically-relevant alterations in trough serum concentration and pharmacodynamics of denosumab (creatinine adjusted urinary N‑telopeptide, uNTx/Cr) by concomitant chemotherapy and/or hormone therapy or by previous intravenous bisphosphonate exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p><u>&nbsp;</u></p><p>There are no or limited amount of data from the use of denosumab in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).&nbsp;</p><p>&nbsp;</p><p>XGEVA is not recommended for use in pregnant women and women of child‑bearing potential not using contraception. Women should be advised not to become pregnant during and for at least 5&nbsp;months after treatment with XGEVA.<strong> </strong>Any effects of XGEVA are likely to be greater during the second and third trimesters of pregnancy since monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester.</p><p>&nbsp;</p><p><u>Breast-feeding </u></p><p><u>&nbsp;</u></p><p>It is unknown whether denosumab is excreted in human milk. A risk to the newborns/infants cannot be excluded. Knockout mouse studies suggest absence of RANKL during pregnancy may interfere with maturation of the mammary gland leading to impaired lactation post-partum (see section 5.3). A decision must be made on whether to abstain from breast-feeding or to abstain from XGEVA therapy taking into account the benefit of breast-feeding to the newborn/infant and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility </u></p><p><u>&nbsp;</u></p><p>No data are available on the effect of denosumab on human fertility. Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>XGEVA has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>Overall safety profile is consistent in all approved indications for XGEVA.</p><p>&nbsp;</p><p>Hypocalcaemia has very commonly been reported following XGEVA administration, mostly within the first 2 weeks. Hypocalcaemia can be severe and symptomatic (see section 4.8 - description of selected adverse reactions). The decreases in serum calcium were generally appropriately managed by calcium and vitamin D supplementation. The most common adverse reactions with XGEVA are musculoskeletal pain. Cases of osteonecrosis of the jaw (see sections 4.4 and section 4.8- description of selected adverse reactions) have been commonly observed in patients taking XGEVA.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The following convention has been used for the classification of the adverse reactions based on incidence rates in four phase III, two phase II clinical studies and post-marketing experience (see table 1): very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare&nbsp;(&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1. Adverse reactions reported in</strong><strong> patients with advanced malignancies involving bone,</strong><strong> </strong><strong>multiple myeloma, or with giant cell tumour of bone</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA </strong><strong>system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>New primary malignancy<sup>1</sup></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Drug hypersensitivity<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction<sup>1</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypocalcaemia<sup>1, 2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypophosphataemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tooth extraction</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lichenoid drug eruptions<sup>1</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Musculoskeletal pain<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Osteonecrosis of the jaw<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Atypical femoral fracture<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Osteonecrosis of the external auditory canal<sup>3,4</sup></p></td></tr></tbody></table><p><sup>1 </sup>See section Description of selected adverse reactions</p><p><sup>2</sup> See section Other special populations</p><p><sup>3</sup> See section 4.4</p><p><sup>4 </sup>Class effect</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Hypocalcaemia</em></p><p>A higher incidence of hypocalcaemia among subjects treated with denosumab compared to zoledronic acid has been observed in (skeletal related events) SRE prevention clinical trials.</p><p>&nbsp;</p><p>The highest incidence of hypocalcaemia was observed in a phase III trial in patients with multiple myeloma. Hypocalcaemia was reported in 16.9% of patients treated with XGEVA and 12.4% of patients treated with zoledronic acid. A grade 3 decrease in serum calcium levels was experienced in 1.4% of patients treated with XGEVA and 0.6% of patients treated with zoledronic acid. A grade 4 decrease in serum calcium levels was experienced in 0.4% of patients treated with XGEVA and 0.1% of patients treated with zoledronic acid.</p><p>&nbsp;</p><p>In three phase III active-controlled clinical trials in patients with advanced malignancies involving bone, hypocalcaemia was reported in 9.6% of patients treated with XGEVA and 5.0% of patients treated with zoledronic acid.</p><p>&nbsp;</p><p>A grade&nbsp;3 decrease in serum calcium levels was experienced in 2.5% of patients treated with XGEVA and 1.2% of patients treated with zoledronic acid. A grade&nbsp;4 decrease in serum calcium levels was experienced in 0.6% of patients treated with XGEVA and 0.2% of patients treated with zoledronic acid (see section 4.4).</p><p>&nbsp;</p><p>In two phase II single-arm clinical trials in patients with giant cell tumour of bone, hypocalcaemia was reported in 5.7% of patients. None of the adverse events was considered serious.</p><p>&nbsp;</p><p>In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported, with most cases occurring in the first weeks of initiating therapy. Examples of clinical manifestations of severe symptomatic hypocalcaemia have included QT interval prolongation, tetany, seizures and altered mental status (including coma) (see section 4.4). Symptoms of hypocalcaemia in clinical studies included paraesthesias or muscle stiffness, twitching, spasms and muscle cramps.</p><p>&nbsp;</p><p><em>Osteonecrosis of the jaw (ONJ)</em></p><p>In clinical trials, the incidence of ONJ was higher with longer duration of exposure; ONJ has also been diagnosed after stopping treatment with XGEVA with the majority of cases occurring within 5&nbsp;months after the last dose. Patients with prior history of ONJ or osteomyelitis of the jaw, an active dental or jaw condition requiring oral surgery, non-healed dental/oral surgery, or any planned invasive dental procedure were excluded from the clinical trials.</p><p>&nbsp;</p><p>A higher incidence of ONJ among subjects treated with denosumab compared to zoledronic acid has been observed in SRE prevention clinical trials. The highest incidence of ONJ was observed in a phase III trial in patients with multiple myeloma. In the double-blind treatment phase of this trial, ONJ was confirmed in 5.9% of patients treated with XGEVA (median exposure of 19.4 months; range 1&nbsp;-&nbsp;52) and in 3.2% of patients treated with zoledronic acid. At the completion of the double-blind treatment phase of this trial, the patient-year adjusted incidence&nbsp; of confirmed ONJ in the XGEVA group (median exposure of 19.4 months; range 1 - 52), was 2.0 per 100&nbsp;patient‑years during the first year of treatment, 5.0 in the second year, and 4.5 thereafter. The median time to ONJ was 18.7 months (range:&nbsp;1&nbsp;- 44).</p><p>&nbsp;</p><p>In the primary treatment phases of three phase III active-controlled clinical trials in patients with advanced malignancies involving bone, ONJ was confirmed in 1.8% of patients treated with XGEVA (median exposure of 12.0&nbsp;months; range 0.1&nbsp;&ndash;&nbsp;40.5) and 1.3% of patients treated with zoledronic acid. Clinical characteristics of these cases were similar between treatment groups. Among subjects with confirmed ONJ, most (81% in both treatment groups) had a history of tooth extraction, poor oral hygiene, and/or use of a dental appliance. Most subjects were receiving or had received chemotherapy.</p><p>&nbsp;</p><p>The trials in patients with breast or prostate cancer included an XGEVA extension treatment phase (median overall exposure of 14.9&nbsp;months; range 0.1&nbsp;&ndash;&nbsp;67.2). ONJ was confirmed in 6.9% of patients with breast cancer and prostate cancer during the extension treatment phase.</p><p>&nbsp;</p><p>The patient-year adjusted overall incidence of confirmed ONJ was 1.1 per 100&nbsp;patient‑years during the first year of treatment, 3.7 in the second year and 4.6 thereafter<em>. </em>The median time to ONJ was 20.6&nbsp;months (range: 4&nbsp;-&nbsp;53).</p><p>&nbsp;</p><p>&nbsp;</p><p>In a phase III trial in patients with non-metastatic prostate cancer (a patient population for which XGEVA is not indicated), with longer treatment exposure of up to 7&nbsp;years, the patient-year adjusted incidence of confirmed ONJ was 1.1 per 100 patient-years during the first year of treatment, 3.0 in the second year, and 7.1 thereafter.</p><p>&nbsp;</p><p>In a long-term phase&nbsp;II open-label clinical trial in patients with giant cell tumour of bone (study&nbsp;6, see section&nbsp;5.1), ONJ was confirmed in 6.8% of patients, including one adolescent&nbsp;(median number of 34&nbsp;doses; range&nbsp;4&nbsp;&ndash;&nbsp;116). At the completion of the trial, median time on trial including safety follow‑up phase was 60.9&nbsp;months (range:&nbsp;0&nbsp;&ndash;&nbsp;112.6). The patient‑year adjusted incidence of confirmed ONJ was 1.5 per 100&nbsp;patient‑years overall (0.2 per 100&nbsp;patient‑years during the first year of treatment, 1.5 in the second year, 1.8 in the third year, 2.1 in the fourth year, 1.4 in the fifth year, and 2.2 thereafter). The median time to ONJ was 41&nbsp;months (range:&nbsp;11&nbsp;-&nbsp;96).</p><p>&nbsp;</p><p><em>Drug related hypersensitivity reactions</em></p><p>In the post-marketing setting, events of hypersensitivity, including rare events of anaphylactic reactions, have been reported in patients receiving XGEVA.</p><p>&nbsp;</p><p><em>Atypical fractures of the femur </em></p><p>In the clinical trial programme, atypical femoral fractures have been reported uncommonly in patients treated with XGEVA&nbsp; and the risk increased with longer duration of treatment. Events have occurred during treatment and up to 9&nbsp;months after treatment was discontinued (see section 4.4).</p><p>&nbsp;</p><p><em>Musculoskeletal pain</em></p><p>In the post-marketing setting, musculoskeletal pain, including severe cases, has been reported in patients receiving XGEVA. In clinical trials, musculoskeletal pain was very common in both the denosumab and zoledronic acid treatment groups. Musculoskeletal pain leading to discontinuation of study treatment was uncommon.</p><p>&nbsp;</p><p><em>New primary malignancy</em></p><p>In the primary double-blind treatment phases of four phase III active-controlled clinical trials in patients with advanced malignancies involving bone, new primary malignancy was reported in 54/3691 (1.5%) of patients treated with XGEVA (median exposure of 13.8 months; range: 1.0 &ndash; 51.7) and 33/3688 (0.9%) of patients treated with zoledronic acid (median exposure of 12.9 months; range: 1.0 - 50.8).</p><p>&nbsp;</p><p>The cumulative incidence at one year was 1.1 %&nbsp;for denosumab and 0.6 % for zoledronic acid, respectively.</p><p>&nbsp;</p><p>No treatment-related pattern in individual cancers or cancer groupings was apparent.</p><p>&nbsp;</p><p>Lichenoid drug eruptions</p><p>Lichenoid drug eruptions (e.g. lichen planus-like reactions), have been reported in patients in the post‑marketing setting.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>XGEVA was studied in an open‑label trial that enrolled 28 skeletally mature adolescents with giant cell tumour of bone. Based on these limited data, the adverse event profile appeared to be similar to adults.</p><p>&nbsp;</p><p>Clinically significant hypercalcaemia after treatment discontinuation has been reported in the post‑marketing setting in paediatric patients (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Other special populations</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment</em><em> </em></p><p>In a clinical study of patients without advanced cancer with severe renal impairment (creatinine clearance&nbsp;&lt;&nbsp;30&nbsp;mL/min) or receiving dialysis, there was a greater risk of developing hypocalcaemia in the absence of calcium supplementation.<em> </em>The risk of developing hypocalcaemia during XGEVA treatment is greater with increasing degree of renal impairment. In a clinical study in patients without advanced cancer, 19% of patients with severe renal impairment (creatinine clearance&nbsp;&lt;&nbsp;30&nbsp;mL/min) and 63% of patients receiving dialysis developed hypocalcaemia despite calcium supplementation. The overall incidence of clinically significant hypocalcaemia was 9%.</p><p>&nbsp;</p><p>Accompanying increases in parathyroid hormone have also been observed in patients receiving XGEVA with severe renal impairment or receiving dialysis. Monitoring of calcium levels and adequate intake of calcium and vitamin D is especially important in patients with renal impairment (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit‑risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:592px"><tbody><tr><td style="vertical-align:top"><p>Reporting to National Regulatory Authority:</p><p>&nbsp;</p><p>To report any side effects:</p><p>&nbsp;</p><p>Saudi Arabia</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Center (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at: +966-11-2038222, Ext 2317-2356-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdose in clinical studies. XGEVA has been administered in clinical studies using doses up to 180&nbsp;mg every 4&nbsp;weeks and 120&nbsp;mg weekly for 3&nbsp;weeks.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for treatment of bone diseases &ndash; other drugs affecting bone structure and mineralisation, ATC code: M05BX04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>RANKL exists as a transmembrane or soluble protein. RANKL is essential for the formation, function and survival of osteoclasts, the sole cell type responsible for bone resorption. Increased osteoclast activity, stimulated by RANKL, is a key mediator of bone destruction in metastatic bone disease and multiple myeloma. Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction.</p><p>&nbsp;</p><p>Giant cell tumours of bone are characterised by neoplastic stromal cells expressing RANK ligand and osteoclast-like giant cells expressing RANK. In patients with giant cell tumour of bone, denosumab binds to RANK ligand, significantly reducing or eliminating osteoclast-like giant cells. Consequently, osteolysis is reduced and proliferative tumour stroma is replaced with non-proliferative, differentiated, densely woven new bone.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>In phase II clinical studies of patients with advanced malignancies involving bone, subcutaneous (SC) dosing of XGEVA administered either every 4&nbsp;weeks (4Q4W) or every 12&nbsp;weeks resulted in a rapid reduction in markers of bone resorption (uNTx/Cr, serum CTx), with median reductions of approximately 80% for uNTx/Cr occurring within 1&nbsp;week regardless of prior bisphosphonate therapy or baseline uNTx/Cr level. In phase III clinical trials of patients with advanced malignancies involving bone, median uNTx/Cr reductions of approximately 80% were maintained through 49&nbsp;weeks of XGEVA treatment (120&nbsp;mg every Q4W).</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>In clinical studies, neutralising antibodies have not been observed for denosumab in advanced cancer patients or giant cell tumour of bone patients. Using a sensitive immunoassay&nbsp;&lt;&nbsp;1% of patients treated with denosumab for up to 3&nbsp;years tested positive for non neutralising binding antibodies with no evidence of altered pharmacokinetics, toxicity, or clinical response.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in patients with bone metastases from solid tumours</u></p><p><u>&nbsp;</u></p><p>Efficacy and safety of 120&nbsp;mg XGEVA SC every 4&nbsp;weeks or 4&nbsp;mg zoledronic acid (dose-adjusted for reduced renal function) IV every 4&nbsp;weeks were compared in three randomised, double‑blind, active‑controlled studies, in IV-bisphosphonate na&iuml;ve patients with advanced malignancies involving bone: adults with breast cancer (study 1), other solid tumours or multiple myeloma (study 2), and castrate-resistant prostate cancer (study&nbsp;3). Within these active-controlled clinical trials, safety was evaluated in 5,931 patients. Patients with prior history of ONJ or osteomyelitis of the jaw, an active dental or jaw condition requiring oral surgery, non-healed dental/oral surgery, or any planned invasive dental procedure, were not eligible for inclusion in these studies. The primary and secondary endpoints evaluated the occurrence of one or more SREs. In studies demonstrating superiority of XGEVA to zoledronic acid, patients were offered open‑label XGEVA in a pre-specified 2-year extension treatment phase. An SRE was defined as any of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.</p><p>&nbsp;</p><p>XGEVA reduced the risk of developing a SRE, and developing multiple SREs (first and subsequent) in patients with bone metastases from solid tumours (see table 2).</p><p>&nbsp;</p><p><strong>Table 2. Efficacy results in patients with advanced malignancies involving bone</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 1</strong></p><p><strong>breast cancer </strong></p><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 2</strong></p><p><strong>&nbsp;other solid tumours** </strong></p><p><strong>or multiple myeloma</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 3</strong></p><p><strong>prostate cancer</strong></p><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Combined</strong></p><p><strong>advanced cancer</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>XGEVA</p></td><td style="vertical-align:top"><p>zoledronic acid</p></td><td style="vertical-align:top"><p>XGEVA</p></td><td style="vertical-align:top"><p>zoledronic acid</p></td><td style="vertical-align:top"><p>XGEVA</p></td><td style="vertical-align:top"><p>zoledronic acid</p></td><td style="vertical-align:top"><p>XGEVA</p></td><td style="vertical-align:top"><p>zoledronic acid</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>1,026</p></td><td style="vertical-align:top"><p>1,020</p></td><td style="vertical-align:top"><p>886</p></td><td style="vertical-align:top"><p>890</p></td><td style="vertical-align:top"><p>950</p></td><td style="vertical-align:top"><p>951</p></td><td style="vertical-align:top"><p>2,862</p></td><td style="vertical-align:top"><p>2,861</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>First SRE</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>26.4</p></td><td style="vertical-align:top"><p>20.6</p></td><td style="vertical-align:top"><p>16.3</p></td><td style="vertical-align:top"><p>20.7</p></td><td style="vertical-align:top"><p>17.1</p></td><td style="vertical-align:top"><p>27.6</p></td><td style="vertical-align:top"><p>19.4</p></td></tr><tr><td style="vertical-align:top"><p>Difference in median time (months)</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td><td colspan="2" style="vertical-align:top"><p>4.2</p></td><td colspan="2" style="vertical-align:top"><p>3.5</p></td><td colspan="2" style="vertical-align:top"><p>8.2</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) / RRR (%)</p></td><td colspan="2" style="vertical-align:top"><p>0.82 (0.71, 0.95) / 18</p></td><td colspan="2" style="vertical-align:top"><p>0.84 (0.71, 0.98) / 16</p></td><td colspan="2" style="vertical-align:top"><p>0.82 (0.71, 0.95) / 18</p></td><td colspan="2" style="vertical-align:top"><p>0.83 (0.76, 0.90) / 17</p></td></tr><tr><td style="vertical-align:top"><p>Non-inferiority / Superiority p-values</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001<strong><sup>&dagger; </sup></strong><strong>/ </strong>0.0101<strong><sup>&dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>0.0007<strong><sup>&dagger;</sup></strong><strong> / </strong>0.0619<strong><sup>&dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>0.0002<strong><sup>&dagger;</sup></strong><strong> / </strong>0.0085<strong><sup>&dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001 / &lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of subjects (%)</p></td><td style="vertical-align:top"><p>30.7</p></td><td style="vertical-align:top"><p>36.5</p></td><td style="vertical-align:top"><p>31.4</p></td><td style="vertical-align:top"><p>36.3</p></td><td style="vertical-align:top"><p>35.9</p></td><td style="vertical-align:top"><p>40.6</p></td><td style="vertical-align:top"><p>32.6</p></td><td style="vertical-align:top"><p>37.8</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>First and subsequent SRE*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean number/patient</p></td><td style="vertical-align:top"><p>0.46</p></td><td style="vertical-align:top"><p>0.60</p></td><td style="vertical-align:top"><p>0.44</p></td><td style="vertical-align:top"><p>0.49</p></td><td style="vertical-align:top"><p>0.52</p></td><td style="vertical-align:top"><p>0.61</p></td><td style="vertical-align:top"><p>0.48</p></td><td style="vertical-align:top"><p>0.57</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio (95% CI) / RRR (%)</p></td><td colspan="2" style="vertical-align:top"><p>0.77 (0.66, 0.89) / 23</p></td><td colspan="2" style="vertical-align:top"><p>0.90 (0.77, 1.04) / 10</p></td><td colspan="2" style="vertical-align:top"><p>0.82 (0.71, 0.94) / 18</p></td><td colspan="2" style="vertical-align:top"><p>0.82 (0.75, 0.89) / 18</p></td></tr><tr><td style="vertical-align:top"><p>Superiority p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0012<strong><sup>&dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>0.1447<strong><sup>&dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>0.0085<strong><sup>&dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>SMR per Year</p></td><td style="vertical-align:top"><p>0.45</p></td><td style="vertical-align:top"><p>0.58</p></td><td style="vertical-align:top"><p>0.86</p></td><td style="vertical-align:top"><p>1.04</p></td><td style="vertical-align:top"><p>0.79</p></td><td style="vertical-align:top"><p>0.83</p></td><td style="vertical-align:top"><p>0.69</p></td><td style="vertical-align:top"><p>0.81</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>First SRE or HCM</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top"><p>19.0</p></td><td style="vertical-align:top"><p>14.4</p></td><td style="vertical-align:top"><p>20.3</p></td><td style="vertical-align:top"><p>17.1</p></td><td style="vertical-align:top"><p>26.6</p></td><td style="vertical-align:top"><p>19.4</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) / RRR (%)</p></td><td colspan="2" style="vertical-align:top"><p>0.82 (0.70, 0.95) / 18</p></td><td colspan="2" style="vertical-align:top"><p>0.83 (0.71, 0.97) / 17</p></td><td colspan="2" style="vertical-align:top"><p>0.83 (0.72, 0.96) / 17</p></td><td colspan="2" style="vertical-align:top"><p>0.83 (0.76, 0.90) / 17</p></td></tr><tr><td style="vertical-align:top"><p>Superiority p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0074</p></td><td colspan="2" style="vertical-align:top"><p>0.0215</p></td><td colspan="2" style="vertical-align:top"><p>0.0134</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>First radiation to bone</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>28.6</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>33.2</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) / RRR (%)</p></td><td colspan="2" style="vertical-align:top"><p>0.74 (0.59, 0.94) / 26</p></td><td colspan="2" style="vertical-align:top"><p>0.78 (0.63, 0.97) / 22</p></td><td colspan="2" style="vertical-align:top"><p>0.78 (0.66, 0.94) / 22</p></td><td colspan="2" style="vertical-align:top"><p>0.77 (0.69, 0.87) / 23</p></td></tr><tr><td style="vertical-align:top"><p>Superiority p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0121</p></td><td colspan="2" style="vertical-align:top"><p>0.0256</p></td><td colspan="2" style="vertical-align:top"><p>0.0071</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr></tbody></table><p>NR = not reached; NA = not available; HCM = hypercalcaemia of malignancy; SMR = skeletal morbidity rate; HR = Hazard Ratio; RRR = Relative Risk Reduction &dagger;Adjusted p-values are presented for Studies 1, 2 and 3 (first SRE and first and subsequent SRE endpoints); *Accounts for all skeletal events over time; only events occurring &ge; 21&nbsp;days after the previous event are counted.</p><p>** Including NSCLC, renal cell cancer, colorectal cancer, small cell lung cancer, bladder cancer, head and neck cancer, GI/genitourinary cancer and others, excluding breast and prostate cancer</p><p>&nbsp;</p><p>Figure 1. Kaplan-Meier plots of time to first on-study SRE</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='position:absolute;margin-left:1.85pt;margin-top:.85pt;
 width:550.3pt;height:231.95pt;z-index:251657216' coordorigin="1455,5979"
 coordsize="11006,4639">
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  left:1580;top:9766;width:8996;height:852;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1027;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt;
     font-family:"Arial Narrow",sans-serif;mso-ansi-language:EN-US'>Dmab =
     Denosumab 120 mg Q4W<o:p></o:p></span></p>
     <p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt;
     font-family:"Arial Narrow",sans-serif;mso-ansi-language:EN-US'>ZA =
     Zoledronic Acid 4 mg Q4W<o:p></o:p></span></p>
     <p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt;
     font-family:"Arial Narrow",sans-serif;mso-ansi-language:EN-US'>N = Number
     of subjects randomised<o:p></o:p></span></p>
     <p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt;
     font-family:"Arial Narrow",sans-serif;mso-ansi-language:EN-US'>* =
     Statistically significant for superiority; ** = Statistically significant
     for non‑inferiority<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;
  left:1677;top:9269;width:10784;height:319;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1028' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
      width="76%" style='width:76.5%;margin-left:34.7pt;border-collapse:collapse;
      mso-yfti-tbllook:1184;mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-border-insideh:
      .5pt solid windowtext'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes;
       height:13.45pt'>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>0<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>6<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>12<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>18<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>24<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>30<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>0<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>6<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>12<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>18<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>24<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>30<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>0<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>6<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>12<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>18<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>24<o:p></o:p></span></p>
       </td>
       <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
       height:13.45pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>30<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
  left:2225;top:9523;width:8351;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1029;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'>Study Month<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1030" type="#_x0000_t202" style='position:absolute;
  left:1686;top:6437;width:472;height:3140;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1030' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
      style='border-collapse:collapse;mso-yfti-tbllook:1184;mso-padding-alt:
      0in 5.4pt 0in 5.4pt;mso-border-insidev:.5pt solid windowtext'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:19.95pt'>
       <td width=38 style='width:28.6pt;padding:0in 5.4pt 0in 5.4pt;height:
       19.95pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>1.0<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:1;height:18.7pt;mso-height-rule:exactly'>
       <td width=38 style='width:28.6pt;padding:0in 5.4pt 0in 5.4pt;height:
       18.7pt;mso-height-rule:exactly'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.8<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:2;height:19.2pt'>
       <td width=38 style='width:28.6pt;padding:0in 5.4pt 0in 5.4pt;height:
       19.2pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.6<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:3;height:18.7pt;mso-height-rule:exactly'>
       <td width=38 style='width:28.6pt;padding:0in 5.4pt 0in 5.4pt;height:
       18.7pt;mso-height-rule:exactly'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.4<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:4;height:19.2pt'>
       <td width=38 style='width:28.6pt;padding:0in 5.4pt 0in 5.4pt;height:
       19.2pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.2<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:5;height:20.6pt'>
       <td width=38 style='width:28.6pt;padding:0in 5.4pt 0in 5.4pt;height:
       20.6pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.0<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes;height:18.7pt;mso-height-rule:
       exactly'>
       <td width=38 style='width:28.6pt;padding:0in 5.4pt 0in 5.4pt;height:
       18.7pt;mso-height-rule:exactly'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>Dmab<br>
       ZA<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1031" type="#_x0000_t202" style='position:absolute;
  left:1455;top:6224;width:246;height:2949;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
   mso-next-textbox:#_x0000_s1031' inset=".5mm,.5mm,.5mm,.5mm">
   <![if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'>Proportion of subjects without SRE<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1032" type="#_x0000_t202" style='position:absolute;
  left:2225;top:5979;width:8503;height:233;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1032' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
      style='border-collapse:collapse;mso-yfti-tbllook:1184;mso-padding-alt:
      0in 5.4pt 0in 5.4pt;mso-border-insideh:.5pt solid windowtext'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
       <td width=196 valign=top style='width:147.15pt;padding:0in 5.4pt 0in 5.4pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>Study 1*<o:p></o:p></span></p>
       </td>
       <td width=184 valign=top style='width:138.25pt;padding:0in 5.4pt 0in 5.4pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>Study 2**<o:p></o:p></span></p>
       </td>
       <td width=184 valign=top style='width:138.2pt;padding:0in 5.4pt 0in 5.4pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>Study 3*<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;
  left:2889;top:6278;width:1160;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1033;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>Dmab (N = 1026)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1034" type="#_x0000_t202" style='position:absolute;
  left:2886;top:6485;width:1160;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1034;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>ZA (N = 1020)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1035" type="#_x0000_t202" style='position:absolute;
  left:5767;top:6278;width:1160;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1035;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>Dmab (N = 886)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1036" type="#_x0000_t202" style='position:absolute;
  left:5762;top:6485;width:1160;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1036;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>ZA (N = 890)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1037" type="#_x0000_t202" style='position:absolute;
  left:8562;top:6282;width:1160;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1037;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>Dmab (N = 950)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1038" type="#_x0000_t202" style='position:absolute;
  left:8555;top:6489;width:1160;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1038;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>ZA (N = 951)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1039" type="#_x0000_t202" style='position:absolute;
  left:2225;top:8763;width:2787;height:420;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1039' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <div align=center>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
      width="96%" style='border-collapse:collapse;mso-table-layout-alt:fixed;
      mso-yfti-tbllook:1184;mso-padding-alt:0in 0in 0in 0in'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:10.05pt'>
       <td width=31 valign=top style='width:23.55pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>1026<o:p></o:p></span></p>
       </td>
       <td width=33 valign=top style='width:24.5pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>697<o:p></o:p></span></p>
       </td>
       <td width=32 valign=top style='width:23.8pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>514<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:26.6pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>306<o:p></o:p></span></p>
       </td>
       <td width=33 valign=top style='width:24.5pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>99<o:p></o:p></span></p>
       </td>
       <td width=12 valign=top style='width:8.9pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>4<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes;height:10.7pt'>
       <td width=31 valign=top style='width:23.55pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>1020<o:p></o:p></span></p>
       </td>
       <td width=33 valign=top style='width:24.5pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>676<o:p></o:p></span></p>
       </td>
       <td width=32 valign=top style='width:23.8pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>498<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:26.6pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>296<o:p></o:p></span></p>
       </td>
       <td width=33 valign=top style='width:24.5pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>94<o:p></o:p></span></p>
       </td>
       <td width=12 valign=top style='width:8.9pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>2<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     </div>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1040" type="#_x0000_t202" style='position:absolute;
  left:5103;top:8759;width:2662;height:414;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1040' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
      width="97%" style='border-collapse:collapse;mso-table-layout-alt:fixed;
      mso-yfti-tbllook:1184;mso-padding-alt:0in 0in 0in 0in'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:10.05pt'>
       <td width=33 valign=top style='width:24.5pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>886<o:p></o:p></span></p>
       </td>
       <td width=31 valign=top style='width:23.1pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>387<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:25.9pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>202<o:p></o:p></span></p>
       </td>
       <td width=32 valign=top style='width:23.8pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>96<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:25.9pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>28<o:p></o:p></span></p>
       </td>
       <td width=10 valign=top style='width:7.15pt;padding:0in 0in 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>0<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes;height:10.7pt'>
       <td width=33 valign=top style='width:24.5pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>890<o:p></o:p></span></p>
       </td>
       <td width=31 valign=top style='width:23.1pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>376<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:25.9pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>194<o:p></o:p></span></p>
       </td>
       <td width=32 valign=top style='width:23.8pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>86<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:25.9pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>20<o:p></o:p></span></p>
       </td>
       <td width=10 valign=top style='width:7.15pt;padding:0in 0in 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>2<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1041" type="#_x0000_t202" style='position:absolute;
  left:7889;top:8757;width:2641;height:426;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1041' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
      width="110%" style='border-collapse:collapse;mso-table-layout-alt:fixed;
      mso-yfti-tbllook:1184;mso-padding-alt:0in 1.4pt 0in 0in'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:10.05pt'>
       <td width=31 valign=top style='width:23.1pt;padding:0in 1.4pt 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>950<o:p></o:p></span></p>
       </td>
       <td width=32 valign=top style='width:23.8pt;padding:0in 1.4pt 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>582<o:p></o:p></span></p>
       </td>
       <td width=31 valign=top style='width:23.1pt;padding:0in 1.4pt 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>361<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:26.6pt;padding:0in 1.4pt 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>168<o:p></o:p></span></p>
       </td>
       <td width=31 valign=top style='width:23.1pt;padding:0in 1.4pt 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>70<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:26.0pt;padding:0in 1.4pt 0in 0in;
       height:10.05pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>18<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes;height:10.7pt'>
       <td width=31 valign=top style='width:23.1pt;padding:0in 1.4pt 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>951<o:p></o:p></span></p>
       </td>
       <td width=32 valign=top style='width:23.8pt;padding:0in 1.4pt 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>544<o:p></o:p></span></p>
       </td>
       <td width=31 valign=top style='width:23.1pt;padding:0in 1.4pt 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>299<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:26.6pt;padding:0in 1.4pt 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>140<o:p></o:p></span></p>
       </td>
       <td width=31 valign=top style='width:23.1pt;padding:0in 1.4pt 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>64<o:p></o:p></span></p>
       </td>
       <td width=35 valign=top style='width:26.0pt;padding:0in 1.4pt 0in 0in;
       height:10.7pt'>
       <p class=MsoNormal style='line-height:normal'><span lang=ES
       style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
       ES'>22<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1042" type="#_x0000_t202" style='position:absolute;
  left:10585;top:8739;width:143;height:444;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
   mso-next-textbox:#_x0000_s1042' inset=".5mm,.5mm,.5mm,.5mm">
   <![if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><b style='mso-bidi-font-weight:
     normal'><span style='font-size:4.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:EN-US'>GRH0447 v1<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]></v:textbox>
 </v:shape></v:group><![endif]--><img width="20" height="201" alt="Text Box: Proportion of subjects without SRE" src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><img width="13" height="34" alt="Text Box: GRH0447 v1" src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><img width="737" height="313" src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:469.5pt;
 height:232pt'>
 <v:imagedata src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg"
  o:title="GRH0447 GRAPH MISC NA coloured"/>
</v:shape><![endif]--><img width="626" height="309" src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg" /></p><p>&nbsp;</p><p><u>Disease progression and overall survival</u><u> </u><u>with bone metastases from solid tumours</u></p><p><u>&nbsp;</u></p><p>Disease progression was similar between XGEVA and zoledronic acid in all three studies and in the pre-specified analysis of all three studies combined.</p><p>&nbsp;</p><p>In studies 1, 2 and 3, overall survival was balanced between XGEVA and zoledronic acid in patients with advanced malignancies involving bone: patients with breast cancer (hazard ratio and 95% CI was 0.95 [0.81, 1.11]), patients with prostate cancer (hazard ratio and 95% CI was 1.03 [0.91, 1.17]), and patients with other solid tumours or multiple myeloma (hazard ratio and 95% CI was 0.95 [0.83, 1.08]). A post-hoc analysis in study 2 (patients with other solid tumours or multiple myeloma) examined overall survival for the 3 tumour types used for stratification (non-small cell lung cancer, multiple myeloma, and other). Overall survival was longer for XGEVA in non-small cell lung cancer (hazard ratio [95% CI] of 0.79 [0.65, 0.95]; n&nbsp;=&nbsp;702) and longer for zoledronic acid in multiple myeloma (hazard ratio [95% CI] of 2.26 [1.13, 4.50]; n&nbsp;=&nbsp;180) and similar between XGEVA and zoledronic acid in other tumour types (hazard ratio [95% CI] of 1.08 (0.90, 1.30); n&nbsp;=&nbsp;894). This study did not control for prognostic factors and anti-neoplastic treatments. In a combined pre-specified analysis from studies 1, 2 and 3, overall survival was similar between XGEVA and zoledronic acid (hazard ratio and 95% CI 0.99 [0.91, 1.07]).</p><p>&nbsp;</p><p><u>Effect on pain</u></p><p><u>&nbsp;</u></p><p>The time to pain improvement (i.e., &ge;&nbsp;2-point decrease from baseline in BPI-SF worst pain score) was similar for denosumab and zoledronic acid in each study and the integrated analyses. In a post-hoc analysis of the combined dataset, the median time to worsening pain (&gt;&nbsp;4-point worst pain score) in patients with mild or no pain at baseline was delayed for XGEVA compared to zoledronic acid (198&nbsp;versus 143&nbsp;days) (p&nbsp;=&nbsp;0.0002).</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy in patients with multiple myeloma</u></p><p><u>&nbsp;</u></p><p>XGEVA was evaluated in an international, randomised (1:1), double-blind, active-controlled study comparing XGEVA with zoledronic acid in patients with newly diagnosed multiple myeloma, study&nbsp;4.</p><p>&nbsp;</p><p>In this study, 1,718&nbsp;multiple myeloma patients with at least one bone lesion were randomised to receive 120&nbsp;mg XGEVA subcutaneously every 4 weeks (Q4W) or 4&nbsp;mg zoledronic acid intravenously (IV) every 4&nbsp;weeks (dose-adjusted for renal function). The primary outcome measure was demonstration of non-inferiority of time to first on study skeletal related event (SRE) as compared to zoledronic acid. Secondary outcome measures included superiority of time to first SRE, superiority of time to first and subsequent SRE, and overall survival. An SRE was defined as any of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.</p><p>&nbsp;</p><p>Across both study arms, 54.5%&nbsp;of patients intended to undergo autologous PBSC transplantation, 95.8%&nbsp;patients utilised/planned to utilise a novel anti-myeloma agent (novel therapies include bortezomib, lenalidomide, or thalidomide) in first-line therapy, and 60.7%&nbsp;of patients had a previous SRE. The number of patients across both study arms with ISS stage I, stage II, and stage III at diagnosis were&nbsp;32.4%, 38.2%, and&nbsp;29.3%, respectively.</p><p>&nbsp;</p><p>The median number of doses administered was 16 for XGEVA and 15 for zoledronic acid.</p><p>&nbsp;</p><p>Efficacy results from study 4 are presented in figure 2 and table 3.</p><p>&nbsp;</p><p><strong>Figure 2. Kaplan-Meier plot for time to first on-study SRE in patients with newly diagnosed multiple myeloma</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1043" style='position:absolute;
 margin-left:-34.6pt;margin-top:7.3pt;width:380.95pt;height:225.9pt;z-index:251658240'
 coordorigin="726,6984" coordsize="7619,4518">
 <v:shape id="_x0000_s1044" type="#_x0000_t202" style='position:absolute;
  left:3807;top:7006;width:4273;height:199;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1044;mso-fit-shape-to-text:t'
   inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>Denosumab 120 mg Q4W (N = 859)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1045" type="#_x0000_t202" style='position:absolute;
  left:3816;top:7196;width:4261;height:199;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQCyL4f8GgIAAEcEAAAOAAAAZHJzL2Uyb0RvYy54bWysU9tu2zAMfR+wfxD0vthxmyUw4hRdugwD
um5Auw+gZTkWptskJXb29aPkOO22t2J6ECiJPDw8FNc3g5LkyJ0XRld0Pssp4ZqZRuh9Rb8/7d6t
KPEBdAPSaF7RE/f0ZvP2zbq3JS9MZ2TDHUEQ7cveVrQLwZZZ5lnHFfiZsVzjY2ucgoBHt88aBz2i
K5kVef4+641rrDOMe4+3d+Mj3ST8tuUsfG1bzwORFUVuIe0u7XXcs80ayr0D2wl2pgGvYKFAaEx6
gbqDAOTgxD9QSjBnvGnDjBmVmbYVjKcasJp5/lc1jx1YnmpBcby9yOT/Hyx7OH5zRDTYu4ISDQp7
9MSHQD6YgVxdR31660t0e7ToGAa8R99Uq7f3hv3wRJttB3rPb50zfcehQX7zGJm9CB1xfASp+y+m
wTxwCCYBDa1TUTyUgyA69ul06U3kwvCyWOaL5dWCEoZv8/lqeb1IKaCcoq3z4RM3ikSjog57n9Dh
eO9DZAPl5BKTeSNFsxNSpoPb11vpyBHwn+zSOqP/4SY16SOz18YrEfC3S6EqusrjikmgjJp91E2y
Awg52shX6rOIUbdRwTDUQ+pXUcTgqHBtmhPK6sz4u3Ea0eiM+0VJjz+7ov7nARynRH7W2Jo4BpPh
JqOeDNAMQysaKBnNbRjH5WCd2HeIPDX/Ftu3E0nZZxZnvvhbk+DnyYrj8PKcvJ7nf/MbAAD//wMA
UEsDBBQABgAIAAAAIQAt6pub4QAAAAkBAAAPAAAAZHJzL2Rvd25yZXYueG1sTI9BT4NAEIXvJv6H
zZh4s0upIEWWxpB48KCptcbrwo6AsrOE3bbor3c86WnyMi/vfa/YzHYQR5x870jBchGBQGqc6alV
sH+5v8pA+KDJ6MERKvhCD5vy/KzQuXEnesbjLrSCQ8jnWkEXwphL6ZsOrfYLNyLx791NVgeWUyvN
pE8cbgcZR1Eqre6JGzo9YtVh87k7WAU30VOdVR/7h9hkj9nb97bC5Wul1OXFfHcLIuAc/szwi8/o
UDJT7Q5kvBgUxKs1owcFq4QvG9I0WYOoFSTXCciykP8XlD8AAAD//wMAUEsBAi0AFAAGAAgAAAAh
ALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAU
AAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAU
AAYACAAAACEAsi+H/BoCAABHBAAADgAAAAAAAAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwEC
LQAUAAYACAAAACEALeqbm+EAAAAJAQAADwAAAAAAAAAAAAAAAAB0BAAAZHJzL2Rvd25yZXYueG1s
UEsFBgAAAAAEAAQA8wAAAIIFAAAAAA==
" strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1045;mso-fit-shape-to-text:t'
   inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span style='font-size:8.0pt;
     font-family:"Arial Narrow",sans-serif;mso-ansi-language:EN-US'>Zoledronic
     Acid 4 mg Q4W (N = 859)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1046" type="#_x0000_t202" style='position:absolute;
  left:2569;top:7424;width:513;height:2960;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1046' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=0
      style='border-collapse:collapse;mso-table-layout-alt:fixed;mso-yfti-tbllook:
      1184;mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-border-insidev:.5pt solid windowtext'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:25.5pt'>
       <td width=34 valign=top style='width:25.25pt;padding:0in 5.4pt 0in 5.4pt;
       height:25.5pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>1.0<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:1;height:25.5pt'>
       <td width=34 valign=top style='width:25.25pt;padding:0in 5.4pt 0in 5.4pt;
       height:25.5pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.8<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:2;height:25.5pt'>
       <td width=34 valign=top style='width:25.25pt;padding:0in 5.4pt 0in 5.4pt;
       height:25.5pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.6<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:3;height:25.5pt'>
       <td width=34 valign=top style='width:25.25pt;padding:0in 5.4pt 0in 5.4pt;
       height:25.5pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.4<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:4;height:25.5pt'>
       <td width=34 valign=top style='width:25.25pt;padding:0in 5.4pt 0in 5.4pt;
       height:25.5pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.2<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes;height:25.5pt'>
       <td width=34 valign=top style='width:25.25pt;padding:0in 5.4pt 0in 5.4pt;
       height:25.5pt'>
       <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
       lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0.0<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1047" type="#_x0000_t202" style='position:absolute;
  left:2423;top:6984;width:261;height:3405;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQAKHITcHQIAAFkEAAAOAAAAZHJzL2Uyb0RvYy54bWysVNtu2zAMfR+wfxD0vjjO2iYw4hRdugwD
um5Auw+gZdkWJouapMTu34+Skyzb3or5QSB1OSTPIb2+HXvNDtJ5habk+WzOmTQCa2Xakn9/3r1b
ceYDmBo0GlnyF+n57ebtm/VgC7nADnUtHSMQ44vBlrwLwRZZ5kUne/AztNLQYYOuh0Cua7PawUDo
vc4W8/lNNqCrrUMhvafd++mQbxJ+00gRvjaNl4HpklNuIa0urVVcs80aitaB7ZQ4pgGvyKIHZSjo
GeoeArC9U/9A9Uo49NiEmcA+w6ZRQqYaqJp8/lc1Tx1YmWohcrw90+T/H6x4PHxzTNUlf8+ZgZ4k
epZjYB9wZFfLSM9gfUG3nizdCyPtk8ypVG8fUPzwzOC2A9PKO+dw6CTUlF4eX2YXTyccH0Gq4QvW
FAf2ARPQ2Lg+ckdsMEInmV7O0sRcRAx5vbxa0Ymgo0V+s8iX1ykEFKfX1vnwSWLPolFyR9IndDg8
+BCzgeJ0JQbzqFW9U1onx7XVVjt2AGqTXfqO6H9c04YNMbPXvu9VoGbXqi/5ah6/GASKyNlHUyc7
gNKTTflqcyQx8jYxGMZqTHLlZ3EqrF+IVodTc9MwkhHXxZIIG6i3S+5/7sFJzvRnE9WJ0WkYLh13
6VSXDhjRIY1M4Gwyt2EaoL11qu0o2Kkf7kjRnUpkR+mnxI4lUP8mDY6zFgfk0k+3fv8RNr8AAAD/
/wMAUEsDBBQABgAIAAAAIQBZId983gAAAAoBAAAPAAAAZHJzL2Rvd25yZXYueG1sTI/BTsMwDIbv
SLxDZCQuiKVryTR1TSeENHFCiDE4Z41pKxKnNNlW3h7vxG7+5U+/P1fryTtxxDH2gTTMZxkIpCbY
nloNu/fN/RJETIascYFQwy9GWNfXV5UpbTjRGx63qRVcQrE0GrqUhlLK2HToTZyFAYl3X2H0JnEc
W2lHc+Jy72SeZQvpTU98oTMDPnXYfG8PXkO6e2763cbRy/QqrcPiU/185Frf3kyPKxAJp/QPw1mf
1aFmp304kI3Ccc4yxSgPDwsQZyBXBYi9hkKpOci6kpcv1H8AAAD//wMAUEsBAi0AFAAGAAgAAAAh
ALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAU
AAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAU
AAYACAAAACEAChyE3B0CAABZBAAADgAAAAAAAAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwEC
LQAUAAYACAAAACEAWSHffN4AAAAKAQAADwAAAAAAAAAAAAAAAAB3BAAAZHJzL2Rvd25yZXYueG1s
UEsFBgAAAAAEAAQA8wAAAIIFAAAAAA==
" strokecolor="white" strokeweight="0">
  <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
   mso-next-textbox:#_x0000_s1047;mso-fit-shape-to-text:t' inset=".5mm,.5mm,.5mm,.5mm">
   <![if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     EN-US'>Proportion of subjects without SRE<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1048" type="#_x0000_t202" style='position:absolute;
  left:726;top:10384;width:2410;height:212;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1048' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'>Denosumab 120 mg Q4W<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1049" type="#_x0000_t202" style='position:absolute;
  left:726;top:10582;width:2415;height:201;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' strokecolor="white"
  strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1049' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     EN-US'>Zoledronic Acid 4 mg Q4W<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1050" type="#_x0000_t202" style='position:absolute;
  left:3113;top:10774;width:5232;height:243;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1050' inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=0
      style='border-collapse:collapse;mso-table-layout-alt:fixed;mso-yfti-tbllook:
      1184;mso-padding-alt:0in 0in 0in 0in;mso-border-insideh:.5pt solid windowtext'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
       <td width=24 nowrap valign=top style='width:18.2pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>0<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:18.2pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>3<o:p></o:p></span></p>
       </td>
       <td width=22 nowrap valign=top style='width:16.8pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>6<o:p></o:p></span></p>
       </td>
       <td width=25 valign=top style='width:18.9pt;padding:0in 0in 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>9<o:p></o:p></span></p>
       </td>
       <td width=26 nowrap valign=top style='width:19.6pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>12<o:p></o:p></span></p>
       </td>
       <td width=20 nowrap valign=top style='width:14.7pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>15<o:p></o:p></span></p>
       </td>
       <td width=29 nowrap valign=top style='width:21.7pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>18<o:p></o:p></span></p>
       </td>
       <td width=21 nowrap valign=top style='width:16.1pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>21<o:p></o:p></span></p>
       </td>
       <td width=27 nowrap valign=top style='width:20.3pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>24<o:p></o:p></span></p>
       </td>
       <td width=21 nowrap valign=top style='width:15.4pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>27<o:p></o:p></span></p>
       </td>
       <td width=25 nowrap valign=top style='width:18.9pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>30<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:18.2pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>33<o:p></o:p></span></p>
       </td>
       <td width=22 nowrap valign=top style='width:16.8pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>36<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:18.2pt;padding:0in 1.4pt 0in 0in'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>39<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1051" type="#_x0000_t202" style='position:absolute;
  left:3177;top:10336;width:4946;height:374;visibility:visible;
  mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1051' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=0
      style='border-collapse:collapse;mso-table-layout-alt:fixed;mso-yfti-tbllook:
      1184;mso-padding-alt:0in 0in 0in 0in'>
      <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:9.2pt'>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 0in 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>859<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>583<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>453<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>370<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>303<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>243<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>197<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>160<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>127<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>99<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>77<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>50<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>35<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>22<o:p></o:p></span></p>
       </td>
      </tr>
      <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes;height:9.2pt'>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 0in 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>859<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>595<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>450<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>361<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>288<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>239<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>190<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>152<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>125<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 2.85pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>95<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>69<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>48<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>31<o:p></o:p></span></p>
       </td>
       <td width=24 nowrap valign=top style='width:17.85pt;padding:0in 1.4pt 0in 0in;
       height:9.2pt'>
       <p class=MsoNormal align=center style='text-align:center;line-height:
       normal'><span lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
       mso-ansi-language:ES'>18<o:p></o:p></span></p>
       </td>
      </tr>
     </table>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1052" type="#_x0000_t202" style='position:absolute;
  left:3163;top:11029;width:5040;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1052;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=ES style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;
     mso-ansi-language:ES'>Study Month<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1053" type="#_x0000_t202" style='position:absolute;
  left:1643;top:11247;width:2648;height:255;visibility:visible;
  mso-height-percent:200;mso-wrap-distance-top:3.6pt;
  mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQCSRW7AHAIAAFcEAAAOAAAAZHJzL2Uyb0RvYy54bWysVNtu2zAMfR+wfxD0vthOmyIw4hRdugwD
ugvQ7gMYWbaFyZJGKbG7rx8lJ2m2vRXzgyBK1OHhIenV7dhrdpDolTUVL2Y5Z9IIWyvTVvz70/bd
kjMfwNSgrZEVf5ae367fvlkNrpRz21ldS2QEYnw5uIp3Ibgyy7zoZA9+Zp00dNlY7CGQiW1WIwyE
3utsnuc32WCxdmiF9J5O76dLvk74TSNF+No0XgamK07cQloxrbu4ZusVlC2C65Q40oBXsOhBGQp6
hrqHAGyP6h+oXgm03jZhJmyf2aZRQqYcKJsi/yubxw6cTLmQON6dZfL/D1Z8OXxDpmqqXcGZgZ5q
9CTHwN7bkS2uoj6D8yW5PTpyDCOdk2/K1bsHK354ZuymA9PKO0Q7dBJq4lfEl9nF0wnHR5Dd8NnW
FAf2wSagscE+ikdyMEKnOj2faxO5iBjyZllcL+lK0F2xuL7KFykElKfXDn34KG3P4qbiSLVP6HB4
8CGygfLkEoN5q1W9VVonA9vdRiM7APXJNn1H9D/ctGFDZPba970K1O1a9RVf5vGLQaCMmn0wddoH
UHraE19tjiJG3SYFw7gbU73mSeKo8M7WzyQr2qm7aRpp01n8xdlAnV1x/3MPKDnTn0wsTQxNo3Bp
4KWxuzTACIKqeOBs2m7CND57h6rtKNKpGe6onFuVlH5hdeRP3ZsKcJy0OB6XdvJ6+R+sfwMAAP//
AwBQSwMEFAAGAAgAAAAhAD4H7n7eAAAACgEAAA8AAABkcnMvZG93bnJldi54bWxMj8FOwkAQhu8m
vsNmTLzJlkILlG6JMXoXNMJx6Q5tQ3e2drdQ397xhMeZ+fPN9+eb0bbigr1vHCmYTiIQSKUzDVUK
Pj/enpYgfNBkdOsIFfygh01xf5frzLgrbfGyC5VgCPlMK6hD6DIpfVmj1X7iOiS+nVxvdeCxr6Tp
9ZXhtpVxFKXS6ob4Q607fKmxPO8Gy5T0QFP83u9fv07JsFps388zWSn1+DA+r0EEHMMtDH/6rA4F
Ox3dQMaLVkEcJ5xUMJ9HKxAciJeLGYgjb9IkBlnk8n+F4hcAAP//AwBQSwECLQAUAAYACAAAACEA
toM4kv4AAADhAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQA
BgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAAAAAAAAAAAAAAC8BAABfcmVscy8ucmVsc1BLAQItABQA
BgAIAAAAIQCSRW7AHAIAAFcEAAAOAAAAAAAAAAAAAAAAAC4CAABkcnMvZTJvRG9jLnhtbFBLAQIt
ABQABgAIAAAAIQA+B+5+3gAAAAoBAAAPAAAAAAAAAAAAAAAAAHYEAABkcnMvZG93bnJldi54bWxQ
SwUGAAAAAAQABADzAAAAgQUAAAAA
" strokecolor="white" strokeweight="0">
  <v:textbox style='mso-next-textbox:#_x0000_s1053;mso-fit-shape-to-text:t'
   inset=".5mm,.5mm,.5mm,.5mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=ES
     style='font-size:8.0pt;font-family:"Arial Narrow",sans-serif;mso-ansi-language:
     ES'>N = number of subjects randomised<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--><img width="21" height="231" alt="Text Box: Proportion of subjects without SRE" src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><img width="512" height="305" src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if gte vml 1]><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:367.5pt;height:231.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png"
  o:title="" cropbottom="5472f"/>
</v:shape><![endif]--><img width="490" height="309" src="file:///C:/Users/aalotaib/AppData/Local/Temp/msohtmlclip1/01/clip_image009.jpg" /></p><p>&nbsp;</p><p><strong>Table 3. Efficacy results for XGEVA compared to zoledronic acid in patients with newly diagnosed multiple myeloma</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>XGEVA</strong></p><p><strong>(N&nbsp;=&nbsp;859)</strong></p></td><td style="vertical-align:top"><p><strong>Zoledronic Acid</strong></p><p><strong>(N&nbsp;=&nbsp;859)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>First SRE</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients who had SREs (%)</p></td><td style="vertical-align:top"><p>376 (43.8)</p></td><td style="vertical-align:top"><p>383 (44.6)</p></td></tr><tr><td style="vertical-align:top"><p>Median time to SRE (months)</p></td><td style="vertical-align:top"><p>22.8 (14.7, NE)</p></td><td style="vertical-align:top"><p>23.98 (16.56, 33.31)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.98 (0.85, 1.14)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>First and subsequent SRE</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean number of events/patient</p></td><td style="vertical-align:top"><p>0.66</p></td><td style="vertical-align:top"><p>0.66</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>1.01 (0.89, 1.15)</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal morbidity rate per year</p></td><td style="vertical-align:top"><p>0.61</p></td><td style="vertical-align:top"><p>0.62</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>First SRE or HCM</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td style="vertical-align:top"><p>22.14 (14.26, NE)</p></td><td style="vertical-align:top"><p>21.32 (13.86, 29.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.98 (0.85, 1.12)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>First radiation to bone</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.78 (0.53, 1.14)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.90 (0.70, 1.16)</p></td></tr></tbody></table><p>NE = not estimable</p><p>HCM = hypercalcaemia of malignancy</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in adults and skeletally mature adolescents with giant cell tumour of bone</u></p><p><u>&nbsp;</u></p><p>The safety and efficacy of XGEVA was studied in two phase II open-label, single arm trials (studies 5 and 6) that enrolled 554&nbsp;patients with giant cell tumour of bone that was either unresectable or for which surgery would be associated with severe morbidity. Patients received 120&nbsp;mg XGEVA subcutaneously every 4&nbsp;weeks with a loading dose of 120&nbsp;mg on days&nbsp;8 and&nbsp;15. Patients who discontinued XGEVA then entered the safety follow-up phase for a minimum of 60&nbsp;months. Retreatment with XGEVA while in safety follow-up was allowed for subjects who initially demonstrated a response to XGEVA (e.g. in the case of recurrent disease).</p><p>&nbsp;</p><p>&nbsp;</p><p>Study 5 enrolled 37&nbsp;adult patients with histologically confirmed unresectable or recurrent giant cell tumour of bone. &nbsp;The main outcome measure of the trial was response rate, defined as either at least 90% elimination of giant cells relative to baseline (or complete elimination of giant cells in cases where giant cells represent &lt;&nbsp;5% of tumour cells), or a lack of progression of the target lesion by radiographic measurements in cases where histopathology was not available.</p><p>&nbsp;</p><p>Of the 35&nbsp;patients included in the efficacy analysis, 85.7% (95% CI: 69.7, 95.2) had a treatment response to XGEVA. All 20&nbsp;patients (100%) with histology assessments met response criteria . Of the remaining 15&nbsp;patients, 10 (67%) radiographic measurements showed no progression of the target lesion.</p><p>&nbsp;</p><p>Study 6 enrolled 535&nbsp;adult or skeletally mature adolescents with giant cell tumour of bone.</p><p>&nbsp;</p><p>Of these patients, 28 were aged 12‑17&nbsp;years. Patients were assigned to one of three cohorts: cohort&nbsp;1 included patients with surgically unsalvageable disease (e.g. sacral, spinal, or multiple lesions, including pulmonary metastases); cohort&nbsp;2 included patients with surgically salvageable disease whose planned surgery was associated with severe morbidity (e.g. joint resection, limb amputation, or hemipelvectomy); cohort&nbsp;3 included patients previously participating in study&nbsp;5 and rolled over into this study. The primary objective was to evaluate the safety profile of denosumab in subjects with giant cell tumour of bone. The secondary outcome measures of the study included time to disease progression (based on investigator assessment) for cohort&nbsp;1 and proportion of patients without any surgery at month&nbsp;6 for cohort&nbsp;2.</p><p>&nbsp;</p><p>&nbsp;</p><p><sup>&nbsp;</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>In cohort&nbsp;1 at the final analysis, 28 of the 260 treated patients (10.8%) had disease progression. In cohort&nbsp;2, 219 of the 238 (92.0%; 95% CI: 87.8%, 95.1%) evaluable patients treated with XGEVA had not undergone surgery by month&nbsp;6. Of the 239&nbsp;subjects in cohort&nbsp;2 with baseline target lesion location or on-study location not in lungs or soft tissue, a total of 82&nbsp;subjects (34.3%) were able to avoid on‑study surgery. Overall, efficacy results in skeletally mature adolescents were similar to those observed in adults.</p><p>&nbsp;</p><p><u>Effect on pain</u></p><p><u>&nbsp;</u></p><p>&nbsp;In the final analysis cohorts&nbsp;1 and&nbsp;2 combined, a clinically meaningful reduction in worst pain (i.e. &ge;&nbsp;2-point decrease from baseline) was reported for 30.8% of patients at risk (i.e. those who had a worst pain score of &ge;&nbsp;2 at baseline) within 1&nbsp;week of treatment, and &ge;&nbsp;50% at week&nbsp;5. These pain improvements were maintained at all subsequent evaluations.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with XGEVA in all subsets of the paediatric population in the prevention of skeletal related events in patients with bone metastases and subsets of the paediatric population below the age of 12 in the treatment of giant cell tumour of bone (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>In study 6, XGEVA has been evaluated in a subset of 28&nbsp;adolescent patients (aged 13-17&nbsp;years) with giant cell tumour of bone who had reached skeletal maturity defined by at least 1 mature long bone (e.g., closed epiphyseal growth plate of the humerus) and body weight &ge;&nbsp;45&nbsp;kg. One adolescent subject with surgically unsalvageable disease (N&nbsp;=&nbsp;14) had disease recurrence during initial treatment. Thirteen of the 14&nbsp;subjects with surgically salvageable disease whose planned surgery was associated with severe morbidity had not undergone surgery by month&nbsp;6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Following subcutaneous administration, bioavailability was 62%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Denosumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>In subjects with advanced cancer, who received multiple doses of 120&nbsp;mg every 4&nbsp;weeks an approximate 2-fold accumulation in serum denosumab concentrations was observed and steady-state was achieved by 6&nbsp;months, consistent with time-independent pharmacokinetics. In subjects with multiple myeloma who received 120&nbsp;mg every 4&nbsp;weeks, median trough levels varied by less than 8% between months 6 and 12. In subjects with giant cell tumour of bone who received 120&nbsp;mg every 4&nbsp;weeks with a loading dose on days&nbsp;8 and 15, steady-state levels were achieved within the first month of treatment. Between weeks&nbsp;9 and 49, median trough levels varied by less than 9%. In subjects who discontinued 120&nbsp;mg every 4&nbsp;weeks, the mean half-life was 28&nbsp;days (range 14 to 55&nbsp;days).</p><p>&nbsp;</p><p>A population pharmacokinetic analysis did not indicate clinically significant changes in the systemic exposure of denosumab at steady state with respect to age (18&nbsp;to 87&nbsp;years), race/ethnicity (Blacks, Hispanics, Asians and Caucasians explored), gender or solid tumour types or patients with multiple myeloma. Increasing body weight was associated with decreases in systemic exposure, and vice versa. The alterations were not considered clinically‑relevant, since pharmacodynamic effects based on bone turnover markers were consistent across a wide range of body weight.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p><u>&nbsp;</u></p><p>Denosumab displayed non-linear pharmacokinetics with dose over a wide dose range, but approximately dose-proportional increases in exposure for doses of 60&nbsp;mg (or 1&nbsp;mg/kg) and higher. The non-linearity is likely due to a saturable target-mediated elimination pathway of importance at low concentrations.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>In studies of denosumab (60&nbsp;mg, n&nbsp;=&nbsp;55 and 120&nbsp;mg, n&nbsp;=&nbsp;32) in patients without advanced cancer but with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics of denosumab; thus dose adjustment for renal impairment is not required. There is no need for renal monitoring with XGEVA dosing.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>No specific study in patients with hepatic impairment was performed. In general, monoclonal antibodies are not eliminated via hepatic metabolic mechanisms. The pharmacokinetics of denosumab is not expected to be affected by hepatic impairment.</p><p>&nbsp;</p><p><u>Elderly</u></p><p><u>&nbsp;</u></p><p>No overall differences in safety or efficacy were observed between geriatric patients and younger patients. Controlled clinical studies of XGEVA in patients with advanced malignancies involving bone over age&nbsp;65 revealed similar efficacy and safety in older and younger patients. No dose adjustment is required in elderly patients.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>In skeletally mature adolescents (12‑17&nbsp;years of age) with giant cell tumour of bone who received 120&nbsp;mg every 4&nbsp;weeks with a loading dose on days&nbsp;8 and&nbsp;15, the pharmacokinetics of denosumab were similar to those observed in adult subjects with GCTB.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since the biological activity of denosumab in animals is specific to nonhuman primates, evaluation of genetically engineered (knockout) mice or use of other biological inhibitors of the RANK/RANKL pathway, such as OPG-Fc and RANK-Fc, were used to evaluate the pharmacodynamic properties of denosumab in rodent models.</p><p>&nbsp;</p><p>In mouse bone metastasis models of oestrogen receptor positive and negative human breast cancer, prostate cancer and non small cell lung cancer, OPG-Fc reduced osteolytic, osteoblastic, and osteolytic/osteoblastic lesions, delayed formation of <em>de novo</em> bone metastases, and reduced skeletal tumour growth. When OPG-Fc was combined with hormonal therapy (tamoxifen) or chemotherapy (docetaxel) in these models, there was additive inhibition of skeletal tumour growth in breast, and prostate or lung cancer respectively. In a mouse model of mammary tumour induction, RANK-Fc reduced hormone-induced proliferation in mammary epithelium and delayed tumour formation.</p><p>&nbsp;</p><p>Standard tests to investigate the genotoxicity potential of denosumab have not been evaluated, since such tests are not relevant for this molecule. However, due to its character it is unlikely that denosumab has any potential for genotoxicity.</p><p>&nbsp;</p><p>The carcinogenic potential of denosumab has not been evaluated in long-term animal studies.</p><p>&nbsp;</p><p>In single and repeated dose toxicity studies in cynomolgus monkeys, denosumab doses resulting in 2.7 to 15 times greater systemic exposure than the recommended human dose had no impact on cardiovascular physiology, male or female fertility, or produced specific target organ toxicity.</p><p>&nbsp;</p><p>In a study of cynomolgus monkeys dosed with denosumab during the period equivalent to the first trimester of pregnancy, denosumab doses resulting in 9 times greater systemic exposure than the recommended human dose did not induce maternal toxicity or foetal harm during a period equivalent to the first trimester, although foetal lymph nodes were not examined.</p><p>&nbsp;</p><p>In another study of cynomolgus monkeys dosed with denosumab throughout pregnancy at systemic exposures 12-fold higher than the human dose, there were increased stillbirths and postnatal mortality; abnormal bone growth resulting in reduced bone strength, reduced haematopoiesis, and tooth malalignment; absence of peripheral lymph nodes; and decreased neonatal growth. A no observed adverse effect level for reproductive effects was not established. Following a 6&nbsp;month period after birth, bone related changes showed recovery and there was no effect on tooth eruption. However, the effects on lymph nodes and tooth malalignment persisted, and minimal to moderate mineralisation in multiple tissues was seen in one animal (relation to treatment uncertain). There was no evidence of maternal harm prior to labour; adverse maternal effects occurred infrequently during labour. Maternal mammary gland development was normal.</p><p><s>&nbsp;</s></p><p>In preclinical bone quality studies in monkeys on long-term denosumab treatment, decreases in bone turnover were associated with improvement in bone strength and normal bone histology.</p><p>&nbsp;</p><p>In male mice genetically engineered to express huRANKL (knock-in mice), which were subjected to a transcortical fracture, denosumab delayed the removal of cartilage and remodelling of the fracture callus compared to control, but biomechanical strength was not adversely affected.</p><p>&nbsp;</p><p>In preclinical studies knockout mice lacking RANK or RANKL had an absence of lactation due to inhibition of mammary gland maturation (lobulo-alveolar gland development during pregnancy) and exhibited impairment of lymph node formation. Neonatal RANK/RANKL knockout mice exhibited decreased body weight, reduced bone growth, altered growth plates and lack of tooth eruption. Reduced bone growth, altered growth plates and impaired tooth eruption were also seen in studies of neonatal rats administered RANKL inhibitors, and these changes were partially reversible when dosing of RANKL inhibitor was discontinued. Adolescent primates dosed with denosumab at 2.7 and 15 times (10 and 50&nbsp;mg/kg dose) the clinical exposure had abnormal growth plates. Therefore, treatment with denosumab may impair bone growth in children with open growth plates and may inhibit eruption of dentition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial contains:</p><p>&nbsp;</p><p>Acetic acid, glacial*: (1.8 mg)</p><p>Sodium hydroxide (for pH adjustment to a target of 5.2)*</p><p>Sorbitol (E420): (78.1 mg)</p><p>Polysorbate 20: (0.17 mg)</p><p>Water for injections: (qs)</p><p>* Acetate buffer is formed by mixing acetic acid with sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C&nbsp;&ndash;&nbsp;8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.7&nbsp;mL solution in a single use vial (type I glass) with stopper (fluoropolymer coated elastomeric) and seal (aluminium) with flip-off cap.</p><p>&nbsp;</p><p>Pack sizes of one, three or four.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before administration, the XGEVA solution should be inspected visually. The solution may contain trace amounts of translucent to white proteinaceous particles. Do not inject the solution if it is cloudy or discoloured.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To avoid discomfort at the site of injection, allow the vial to reach controlled room temperature (up to 25&nbsp;&ordm;C) before injecting and inject slowly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The entire contents of the vial should be injected.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A 27 gauge needle is recommended for the administration of denosumab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The vial should not be re-entered.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amgen Europe B.V.
Minervum 7061
NL-4817 ZK Breda
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 November 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>